Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes.

ABSTRACT:

Background

Survival rates for ovarian cancer remain poor, and monitoring and prediction of therapeutic response may benefit from additional markers. Ovarian cancers frequently overexpress Folate Receptor alpha (FRα) and the soluble receptor (sFRα) is measurable in blood. Here we investigated sFRα as a potential biomarker.

Methods

We evaluated sFRα longitudinally, before and during neo-adjuvant, adjuvant and palliative therapies, and tumour FRα expression status by immunohistrochemistry. The impact of free FRα on the efficacy of anti-FRα treatments was evaluated by an antibody-dependent cellular cytotoxicity assay.

Results

Membrane and/or cytoplasmic FRα staining were observed in 52.7% tumours from 316 ovarian cancer patients with diverse histotypes. Circulating sFRα l

SUBMITTER: Bax HJ 

PROVIDER: S-EPMC9902484 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature